We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
Other cookies are those that are being identified and have not been classified into any category as yet.
Cardiff and Vale University Health Board (CAV) needed to rapidly increase the capacity of its Mass Vaccination Programme (MVP) while maintaining flexibility to respond to an unpredictable vaccine supply. In a complex environment involving multiple organisations, Q5 were asked to lead the process to develop options for accelerating the MVP and support the swift implementation of the chosen solution.
Q5 quickly stood up a team in response to the challenge, forming an integrated team across Q5, CAV, and local government bodies Cardiff Council and Vale of Glamorgan Council. The team led a 14-day rapid sprint to ideate, evaluate, and shortlist options for accelerating the pace of the vaccination programme, to be taken forward to implementation by the Health Board.
The sprint provided both focused outcomes that provided incremental improvements to existing processes, patient flow, and capacity within the MVP as well as radical options for significant vaccination acceleration.
Our approach to the sprint included: